



PRESS RELEASE

OCON Medical's Hormone-Free Contraceptive Ballerine Significantly Reduces Uterine Pain and Bleeding

MODIIN, ISRAEL – December 7, 2017 – OCON Medical (OCON), a pioneer in innovative women's health products, today announces that its lead product IUB™ Ballerine® (Ballerine®) reduced bleeding and pain in a cohort of 366 women enrolled in a two-year follow-up trial. Ballerine® is a copper-based hormone-free contraceptive based on OCON's proprietary IUB™ (intrauterine ball) platform.

Data from the prospective, randomized, single blind, two-arm controlled study of healthy women aged 18-42, showed that Ballerine® significantly reduced the incidence of pain and bleeding whilst maintaining efficacy akin to the TCu380 (a market-approved standard T-shaped IUD containing copper). Additionally, use of the device eliminated malposition and showed an overall reduction in the rate of expulsion, issues affecting more than 16% and 10% of standard IUD users respectively.

Ariel Weinstein, CEO of OCON Medical, said: "In terms of best standard of care, it is the hope of every expert in this field to deliver an effective, long term and reversible contraceptive that doesn't disrupt the user's life through pain, discomfort or bleeding.

"Using our proprietary IUB™ platform, we have been able to develop and produce a solution to these problems in a cost effective way and we are confident that we are providing women with a simple and more convenient form of reversible contraception, and an improved quality of life."

Dr Ilan Baram, OCON's founder, Chief Medical Officer and inventor of the IUB™, added: "Every year, there are more than 50,000 cases of a patient's IUD perforating the uterine wall and 20% of all IUD users will opt for removal because of pain and bleeding. The data from this study supports our vision of having the technology succeed in increasing user quality of life."

To date, 60,000 Ballerine® devices have been sold in 17 countries.

It is anticipated that full data will be published in 2018.

OCON Medical's expanding offering is based on its proprietary IUB™ platform, made from Nitinol, a unique, flexible shape memory alloy which, once inserted into the uterus, coils back into a smooth three-dimensional ball. While IUB™ Ballerine® uses the IUB™ frame mounted with copper pearls to deliver hormone-free contraception, the platform can also support intrauterine drug delivery.

ENDS

About OCON Medical

OCON Medical develops, manufactures and commercialises innovative women's health products based on IUB™, its proprietary intrauterine platform. The platform made of a super-elastic alloy Nitinol is an ideal carrier for hormone-free contraception and intrauterine drugs.

OCON's first product IUB™ Ballerine® is a copper-based hormone-free intrauterine contraceptive available in 17 countries. 60,000 units have been sold in Europe since 2014. The Company is also developing a strong pipeline of products using the IUB™ frame for hormonal contraception and additional indications including abnormal uterine bleeding and infertility.

OCON successfully closed a \$7m round of financing in November 2017, welcoming The Chemo Group as a new strategic shareholder through its Exeltis Women's Health Business, among existing shareholders: Pontifax, Docor and RMI.

OCON's technology platform and products are protected by a broad portfolio of patents and trademarks. The private Company, established in 2011, is headquartered in Modiin, Israel.

For more information visit the company website: www.oconmed.com

For further information, please contact:

OCON Medical

Michal Haham

T+ : +972-722-150-105

E: info@oconmed.com

Instinctif Partners (media enquiries)

Gemma Harris/Dr Christelle Kerouedan

T: +44 20 7866 7860

E: OCONMedical@instinctif.com